Milind Javle, MD, The University of Texas MD Anderson Cancer Center

Articles

The Investigational Pipeline for Advanced BTC

May 30th 2024

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss ongoing research efforts in advanced biliary tract cancer.

Factoring in Trastuzumab Deruxtecan in the Advanced BTC Setting

May 30th 2024

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss how to factor in trastuzumab deruxtecan in advanced biliary tract cancer.

Considering Factors When Choosing Among IO Agents in Advanced BTC

May 30th 2024

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss considering factors for immunotherapy agents in advanced biliary tract cancer.

Clinical Implications of 3-Year OS Data With Durvalumab/Chemo in Advanced BTC

May 29th 2024

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss the clinical implications of 3-year survival data from TOPAZ-1 in advanced biliary tract cancer.

Putting TOPAZ-1 Data into Context for Patients With Advanced BTC

May 29th 2024

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient put the TOPAZ-1 data into context for patients with advanced biliary tract cancer.

Homing in on the TOPAZ-1 Trial in Biliary Tract Cancer

May 29th 2024

Milind Javle, MD; Rachna Shroff, MD, MS, FASCO; and a patient discuss the phase 3 TOPAZ-1 trial in advanced biliary tract cancer.

Discussion of a Patient Case of Advanced BTC

May 29th 2024

Milind Javle, MD, and Rachna Shroff, MD, MS, FASCO, discuss a case of advanced biliary tract cancer with a patient.

Prognosis and Standards of Care in Advanced Biliary Tract Cancer

May 29th 2024

Milind Javle, MD, and Rachna Shroff, MD, MS, FASCO, and a patient discuss prognosis and standard-of-care treatment for patients with advanced biliary tract cancer.

The Evolving Treatment Landscape of Biliary Tract Cancers

July 4th 2023

Closing out their discussion on biliary tract cancers, Milind Javle, MD, and Laura Goff, MD, highlight current treatment guidelines and unmet needs as the landscape continues to evolve.

Other Clinical Trials With Chemoimmunotherapy in Biliary Tract Cancers

July 4th 2023

Expert perspectives on the KEYNOTE-966 and IMbrave151 clinical trials and novel chemoimmunotherapy combination strategies in biliary tract cancers.

Chemoimmunotherapy in Biliary Tract Cancers: Data From TOPAZ-1

June 27th 2023

Centering discussion on data from TOPAZ-1, Milind Javle, MD, and Laura Goff, MD, reflect on the value of chemoimmunotherapy combinations in biliary tract cancer management.

Biliary Tract Cancers: Standard of Care Treatment Strategies

June 27th 2023

Drs Javle and Goff review standard of care treatment strategies for the management of biliary tract cancer and discuss recent NCCN guideline updates for the combination of durvalumab + cisplatin + gemcitabine.

What is the Role of Biomarker Testing in Biliary Tract Cancers?

June 20th 2023

Shared insight on the role of molecular testing in the diagnosis of biliary tract cancers and how it may inform the selection of optimal therapy.

Overview of Biliary Tract Cancers and Diagnosis

June 20th 2023

Expert oncologists Milind Javle, MD, and Laura Goff, MD, reflect on the subsets of biliary tract cancers and consider best practices in making an accurate diagnosis.

The Evolving Treatment Landscape of Biliary Tract Cancers

March 22nd 2023

Closing out their discussion on biliary tract cancers, expert panelists share key takeaways and excitement for the evolving treatment paradigm.

Novel Targeted Therapies Under Investigation in Biliary Tract Cancers

March 22nd 2023

Comprehensive insight on novel targeted agents under investigation in the setting of biliary tract cancers.

Biliary Tract Cancers: Combination Strategies With Immune Checkpoint Inhibitors

March 15th 2023

An overview on novel treatment strategies in biliary tract cancers combining immune checkpoint inhibitors with various targeted agents.

TOPAZ-1: Chemotherapy + Durvalumab in Biliary Tract Cancers

March 15th 2023

Centering discussion on the TOPAZ-1 trial of chemotherapy in combination with durvalumab, panelists consider how this regimen has impacted clinical practice.

Standard of Care Systemic Therapies for Biliary Tract Cancers

March 8th 2023

Key opinion leaders in the field of biliary tract cancers highlight mainstay systemic therapy regimens within the treatment paradigm.

Role for Liver Transplant in Biliary Tract Cancers

March 8th 2023

A brief discussion on the continued role of liver transplant in biliary tract cancers and when it is appropriate to consider a patient for this procedure.